-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

Benzinga·09/09/2026 13:23:41
语音播报
Baird analyst Brian Skorney maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $30 to $26.